Grant ID | RP140435 |
Awarded On | August 20, 2014 |
Title | SHH/GLI3 Signaling Axis as a Therapeutic Target in Castration Resistant Prostate Cancer |
Program | Academic Research |
Award Mechanism | High Impact/High Risk |
Institution/Organization | The University of Texas Health Science Center at San Antonio |
Principal Investigator/Program Director | Thomas Boyer |
Cancer Sites | Prostate |
Contracted Amount | $200,000 |
Lay Summary |
Prostate cancer is the most common malignancy and the second leading cause of cancer-associated deaths among US men. Although most prostate cancer patients initially respond to androgen deprivation therapy, they eventually progress to castration resistant prostate cancer (CRPC) characterized by androgen receptor-dependent tumor growth despite castrate levels of circulating androgens. Once patients have reached this stage, treatment options are frustratingly limited and average survival times range from 2-3 years only. Therefore, one of the overarching challenges in the field is to develop effective treatments and address mechanisms of CRPC. This innovative proposal conforms precisely to this... |